There is a groundswell in Africa in support of local pharmaceutical production. Africa’s dependency on the rest of the world for medicines may not last long. <ClickHere>
Tag: patent cliff
What does China’s open policy mean to pharma multinationals?
Multinationals (MNCs) were thrilled by China’s recent policies on opening up the domestic pharmaceutical market to the world. <ClickHere>
Key Business Strategy Tools to Survive a Patent Cliff in the Biopharmaceutical Industry
This case study presents the research gathered in seeking to identify a number of key business strategy tools that biopharmaceutical companies have used to revitalize their growth following the patent cliff. <ClickHere>
Surviving patent expiration: strategies for marketing pharmaceutical products
The pharmaceutical industry is characterized by high R&D costs and increasing competition. New pharmaceutical products are often provided patent protection to help companies recoup their R&D costs. <ClickHere>
NHS England to save £300m after patent expiry of most costly drug
By replacing adalimumab with biosimilar versions, NHS hospitals will only pay a quarter of the £400m they currently spend each year on the drug. <ClickHere>
The key covid-19 compulsory licensing developments so far
Governments are beginning to adopt extraordinary measures to tackle the covid-19 pandemic. Given the seriousness of the current health crisis, and mounting economic pressures, it is little surprise that the prospect of compulsory patent licensing has arisen in a number of countries in recent weeks. <ClickHere>
Coronavirus Patents: China Files for Remdesivir Patent, but Gilead Sciences Will Still Come Out a Winner
On February 4, the Wuhan Institute of Virology announced that it had applied for a Chinese patent on Gilead’s Remdesivir for novel coronavirus treatment in order to protect the national interests of China. <ClickHere>
Medical supply chains are fragile in the best of times and COVID-19 will test their strength
The COVID-19 pandemic has brought medical supply chains into the spotlight. <ClickHere>
Will governments override patent rights in the race to find a cure for COVID-19?
The outbreak of COVID-19 coronavirus has prompted a global race to find a vaccine to fight the disease. <ClickHere>
“Playing Both Sides?” Branded Sales, Generic Sales and Patent Policy
In this article, we explore a phenomenon we call “playing both sides”: companies that participate in pharmaceutical markets as both brand owners and generics. We hypothesize that companies that earn a significant amount of their revenue from patented drugs may have less incentive to aggressively pursue a generic agenda, since patented drugs generate far more revenue for firms than generic drugs do. <ClickHere>